Recent research studies surrounding the medication Retatrutide , specifically the high-dose formulation branded as ZPHC, indicate a significant benefit on weight loss and associated chronic factors. Scientists posit that this dual agonist , targeting both GLP-1 and GIP pathways , could provide a noteworthy improvement in the treatment of obesity an